iCAD Inc. - ICAD Operatsion marja

iCAD Corp - ICAD emitenti grafik logotipi

iCAD, Inc. (ICAD) korporativ kelishuvlar muddatini nazorat qilish bilan birga, daromadlarni barqarorlashtirish uchun bulutli obunalar modeliga o'tmoqda. Ko'krak o'smalarini erta aniqlashda AI algoritmlarining aniqligi tufayli shifokorlarning samaradorligi oshmoqda. Rentgen uskunalarini ishlab chiqaruvchilar bilan tuzilgan texnologik ittifoq diagnostikani transformatsiya qilmoqda. Asosiy biznes marjasi kapital dinamikasini aks ettiradi, bunda -30.50 qiymati soliqlar va foizlardan oldingi joriy operatsion foyda miqdorini ko'rsatadi.

iCAD Inc. (ICAD): Operatsion foyda bo'yicha sotuv rentabelligi 04.07.2022dan 02.08.2025gacha

ICAD (iCAD Inc.): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- emitentning bozor qiymati haqida ma'lumotlar:
Kompaniyaning dastlabki tahlili:iCAD Inc., ICAD
iCAD brendining mahsuloti

iCAD, Inc. (ICAD) kompaniyasining sun'iy intellektga asoslangan onkologik diagnostika sohasidagi R&D loyihalari faol rivojlanishi sezilarli xarajatlarni talab qiladi, bu esa operatsion samaradorlikka bevosita ta'sir ko'rsatadi. Operatsion marja ko'rsatkichlarini tahlil qilish orqali investorlar asosiy biznesdan olingan foydaning foizini foizlar va soliqlar to'lanishidan oldin baholaydilar, bunda grafikning barqaror trayektoriyasi kompaniyaning texnologik yangilanishlarni haqiqiy operatsion daromadga aylantirish qobiliyatini tasdiqlaydi.

Raqobatdosh kompaniyalar tahlili

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|CTOR - Operatsion rentabellik|Operatsion faoliyat rentabelligi tuhurabio.com HURA|Protara Therapeutics, Inc. (TARA) - Operatsion rentabellik|FATE: Operatsion foyda koeffitsiyenti|WHWK (Aadi Bioscience, Inc.) - Operatsion marja|TCRX (TScan Therapeutics) - Operatsion foyda koeffitsiyenti|Operatsion rentabellik Champions Oncology (CSBR)|Operatsion faoliyat rentabelligi XBiotech USA|Operatsion rentabellik CEL-SCI CVM|OS Therapies, Inc. (OSTX) - Sotuvning operatsion rentabelligi|RADX - Operatsion rentabellik|ARTV - Operatsion marja|Adlai Nortye Ltd (ANL) - Operatsion rentabellik|Veru Pharma - Operatsion foyda normasi|Operatsion rentabellik Tempest Therapeutics Corp|Operatsion foyda bo'yicha sotuv rentabelligi XLO (Xilio Therapeutics, Inc.)|Operatsion marja RENB|MURA (Mural Oncology) - Operatsion foyda normasi|Operatsion marja KAPA (Kairos Pharma Ltd)|OKUR: Operatsion foyda bo'yicha sotuv rentabelligi|GDTC: Sotuvning operatsion marjasi|CRIS - Operatsion marja|APLM: Operatsion marja|Sotuvning operatsion rentabelligi tharimmune.com (THAR)|ADVB (Advanced Biomed Corp) - Operatsion marja|Operatsion marja Genprex Inc.|Operatsion marja CLDI|Sotuvning operatsion marjasi Sunshine Biopharma, Inc. SBFM|Operatsion marja XBIO (Xenetic Biosciences)|Operatsion foyda normasi SLRX|PPBT - Operatsion rentabellik|AONC (aoncology.com) - Operatsion foyda bo'yicha sotuv rentabelligi|BGNE: Operatsion marja|Checkpoint Therapeutics Inc (CKPT) - Operatsion marja|ELEV (Elevation Oncology Inc.) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja